HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
RVMD
Revolution Medicines, Inc.
There isn't enough reported data to score RVMD yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
RVMD Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
RVMD's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
RVMD PE Valuation
RVMD has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
RVMD Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Moderate | |
| Low |
Analysts expect RVMD's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has the edge over RVMD on earnings, with more consistent year-over-year improvement.
RVMD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$9.15 | -$4.08 |
| Q2 2026 | -$8.86 | -$4.46 |
| Q1 2026 | -$7.11 | -$3.21 |
| Q4 2025 | -$5.95 | -$2.48 |
| Q3 2025 | -$5.07 | -$1.39 |
| Q2 2025 | -$4.40 | -$0.67 |
| Q1 2025 | -$3.90 | -$0.06 |
| Q4 2024 | -$3.47 | +$0.39 |
RVMD lost $9.15 per share over the past year, a bigger loss than the year before.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS's revenue has grown year over year every quarter since late 2021: $890M last quarter, up 49% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over RVMD on profitability, with a higher operating margin.
RVMD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2023 | $742K | -95% |
| Q2 2023 | $3.8M | -58% |
| Q1 2023 | $7M | -7.4% |
| Q4 2022 | $15.3M | +62% |
| Q3 2022 | $3.4M | +205% |
| Q2 2022 | $9.1M | +4.8% |
| Q1 2022 | $7.6M | -25% |
| Q4 2021 | $9.5M | +8.1% |
RVMD's revenue is growing: $198M last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -189% | N/A |
| Q4 2023 | -24256% | -23854 points |
| Q2 2023 | -2845% | -2164 points |
| Q1 2023 | -1072% | -307 points |
| Q4 2022 | -403% | +157 points |
| Q3 2022 | -2280% | +2548 points |
| Q2 2022 | -681% | -169 points |
| Q1 2022 | -765% | -396 points |
RVMD's operating margin was −189% last quarter, up 214 points from the same quarter a year ago.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over RVMD on cash generation, producing positive trailing cash flow while its opponent burns cash.
RVMD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$419.3M | -$208.7M |
| Q2 2026 | -$389.6M | -$160.4M |
| Q1 2026 | -$355.7M | -$158M |
| Q4 2025 | -$276.2M | -$136.7M |
| Q3 2025 | -$210.7M | -$76.7M |
| Q2 2025 | -$229.2M | -$98.6M |
| Q1 2025 | -$197.7M | -$34M |
| Q4 2024 | -$139.5M | -$16.6M |
RVMD has burned cash in almost every quarter: −$1.4B over the past year, against −$777M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over RVMD on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
RVMD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.9% | +4.1M shares |
| 1 year | +14% | +25.7M shares |
| 3 years | +101% | +108M shares |
| 5 years | +193% | +142M shares |
| Available history | +489% | +178M shares |
RVMD has 215M diluted shares, up 14% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2019 | — |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
RVMD Net Leverage
RVMD's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
RVMD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 49.3 | Neutral |
| Stochastic | 22.2 | Neutral |
RVMD's weekly RSI is 49 (neutral) and its Stochastic is 22 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
RVMD PE vs Healthcare Sector
RVMD has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
RVMD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $190.8 | 7.6% below |
| 20 week MA | $194.8 | 9.5% below |
| 50 week MA | $147.8 | 19% above |
| 100 week MA | $95.6 | 85% above |
| 200 week MA | $64.3 | 174% above |
RVMD has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
RVMD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $28.3 | $42.6 | +51% |
| 2021 | $42.6 | $27.6 | -35% |
| 2022 | $27.6 | $22.0 | -20% |
| 2023 | $22.0 | $28.7 | +30% |
| 2024 | $28.7 | $44.2 | +54% |
| 2025 | $44.2 | $80.8 | +83% |
| 2026 YTD | $80.8 | $176.4 | +118% |
RVMD has the edge over HIMS on returns for 2026, with the stronger performance.